The impact of right ventricular dysfunction on the prognosis and therapy of normotensive patients with pulmonary embolism

被引:176
作者
Kreit, JW [1 ]
机构
[1] Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA
关键词
echocardiography; pulmonary embolism; right ventricular dysfunction; thrombolytic therapy; tissue plasminogen activator; venous thrombosis;
D O I
10.1378/chest.125.4.1539
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
The prognosis and optimal therapy of patients with pulmonary embolism (PE) are strongly influenced by the presence or absence of associated hemodynamic derangements. Patients with normal systemic arterial pressure have a relatively low risk of recurrent PE and death when treated promptly with therapeutic anticoagulation. Those who present with hypotension, shock, or cardiac arrest, however, have a much higher mortality rate and often receive thrombolytic therapy. Recent evidence indicates that the presence of right ventricular (RV) dysfunction identifies a subgroup of normotensive patients with a much more guarded prognosis who may benefit from more intensive therapy with thrombolytic agents. This article reviews our current understanding of the pathophysiology and diagnosis of RV dysfunction and its impact on the prognosis and therapy of normotensive patients with PE.
引用
收藏
页码:1539 / 1545
页数:7
相关论文
共 50 条
[1]   MORTALITY IN PATIENTS TREATED FOR PULMONARY-EMBOLISM [J].
ALPERT, JS ;
SMITH, R ;
CARLSON, CJ ;
OCKENE, IS ;
DEXTER, L ;
DALEN, JE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1976, 236 (13) :1477-1480
[2]   A POPULATION-BASED PERSPECTIVE OF THE HOSPITAL INCIDENCE AND CASE-FATALITY RATES OF DEEP-VEIN THROMBOSIS AND PULMONARY-EMBOLISM - THE WORCESTER DVT STUDY [J].
ANDERSON, FA ;
WHEELER, HB ;
GOLDBERG, RJ ;
HOSMER, DW ;
PATWARDHAN, NA ;
JOVANOVIC, B ;
FORCIER, A ;
DALEN, JE .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (05) :933-938
[3]  
[Anonymous], 1974, JAMA-J AM MED ASSOC, V229, P1606
[4]  
[Anonymous], 1990, CHEST, V97, P528
[5]  
[Anonymous], 1970, J AMER MED ASSOC, V214, P2163
[6]   Thrombolytic therapy of pulmonary embolism - A comprehensive review of current evidence [J].
Arcasoy, SM ;
Kreit, JW .
CHEST, 1999, 115 (06) :1695-1707
[7]   Cardiovascular risk stratification of pulmonary embolism [J].
Cannon, CP ;
Goldhaber, SZ .
AMERICAN JOURNAL OF CARDIOLOGY, 1996, 78 (10) :1149-&
[8]   EARLY REVERSAL OF RIGHT VENTRICULAR DYSFUNCTION IN PATIENTS WITH ACUTE PULMONARY-EMBOLISM AFTER TREATMENT WITH INTRAVENOUS TISSUE PLASMINOGEN-ACTIVATOR [J].
COME, PC ;
KIM, D ;
PARKER, JA ;
GOLDHABER, SZ ;
BRAUNWALD, E ;
MARKIS, JE .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1987, 10 (05) :971-978
[9]   PAIMS-2 - ALTEPLASE COMBINED WITH HEPARIN VERSUS HEPARIN IN THE TREATMENT OF ACUTE PULMONARY-EMBOLISM - PLASMINOGEN-ACTIVATOR ITALIAN MULTICENTER STUDY-2 [J].
DALLAVOLTA, S ;
PALLA, A ;
SANTOLICANDRO, A ;
GIUNTINI, C ;
PENGO, V ;
VISIOLI, O ;
ZONZIN, P ;
ZANUTTINI, D ;
BARBARESI, F ;
AGNELLI, G ;
MORPURGO, M ;
MARINI, MG ;
VISANI, L .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1992, 20 (03) :520-526
[10]   Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism [J].
Giannitsis, E ;
Müller-Bardorff, M ;
Kurowski, V ;
Weidtmann, B ;
Wiegand, U ;
Kampmann, M ;
Katus, HA .
CIRCULATION, 2000, 102 (02) :211-217